Kymera Therapeutics, Inc. (KYMR) intrinsic value & 10-year financials
Kymera Therapeutics, Inc. (KYMR) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 54.0% a year to $39.2M, with an average return on invested capital of -30.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $104.78
- Market cap
- $8.9B
- Revenue (FY2025)
- $39.2M
- Revenue growth (8-yr CAGR)
- 54.0%
- ROIC (10-yr avg)
- -30.3%
- Free cash flow (FY2025)
- -$234.3M
KYMR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $39.2M | -$311.4M | -$3.69 | -$234.3M | -891.1% | -33.6% |
| FY2024 | $47.1M | -$223.9M | -$2.98 | -$207.3M | -555.8% | -38.8% |
| FY2023 | $78.6M | -$147.0M | -$2.52 | -$137.3M | -210.6% | -36.8% |
| FY2022 | $46.8M | -$154.8M | -$2.87 | -$155.9M | -344.4% | -37.5% |
| FY2021 | $72.8M | -$100.2M | -$2.09 | -$130.5M | -138.0% | -29.0% |
| FY2020 | $34.0M | -$45.6M | -$3.15 | $79.0M | -136.1% | -68.6% |
| FY2019 | $2.9M | -$41.2M | — | $17.4M | -1438.5% | 31.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kymera Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kymera Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.3% ROIC.
Kymera Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Kymera Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-122.57 per share.